De novo CD5-positive diffuse large B-cell lymphoma (CD5+DLBCL) is regarded as a different clinicopathological entity from CD5-negative DLBCL (CD5-DLBCL) and mantle cell lymphoma (MCL). Because only a few published cytogenetic studies of de novo CD5+DLBCL are available, we investigated chromosomal changes in 23 Japanese patients who had de novo CD5+DLBCL. A characteristic of cytogenetic abnormalities in de novo CD5+DLBCL was a high incidence of chromosomal aberrations affecting 8p21 and 11q13. Major chromosomal breakpoints were concentrated at 8p21, 11q13, and 3q27. Patients with 8p21 aberrations showed aggressive clinical features, including advanced stage of disease, elevated serum LDH level, poor performance status, and an inferior survival curve compared with patients who had 11q13 changes (P = .043). Chromosomal abnormalities of both 8p21 and 11q13 were not observed in the same patient, and each abnormality showed different chromosomal gains and losses. These results indicate that de novo CD5+DLBCL may occur in previously unidentified subgroups that differ in their chromosomal abnormalities. The conflicting results of previous studies on prognosis may thus be explained in part by the differences in chromosomal changes.
All Science Journal Classification (ASJC) codes
- Cancer Research